Ilya Petrou, M.D.

Ilya Petrou, MD, is a contributing writer for Dermatology Times.

Articles by Ilya Petrou, M.D.

Merkel cell carcinoma (MCC) is a neuroendocrine tumor of the skin that is very aggressive and potentially lethal. As such, treatment approaches and disease management should also be aggressive and appropriately address the patient's disease and symptoms. Treatment choices depend on the stage of the tumor, however, as well as the general health of the affected patient.

Sentinel lymph node biopsy (SLNB) for management of localized primary melanoma continues to have its critics, but Alistair Cochran, M.D., says that current data supports the procedure as a standard approach for staging patients with clinically localized, intermediate-thickness melanoma.

A facial rejuvenation device that delivers fractional bipolar radiofrequency (RF) energy via microneedling directly into the dermis tightens skin and achieves measurable lifting and volume increase the likes of which have never been seen by any other devices on the market, said Lori Brightman, M.D., at the 2012 meeting of the American Society for Laser Medicine and Surgery.

Interferon and the recently Food and Drug Administration-approved pegylated interferon remain relevant adjuvant therapies for patients with lymph node-positive melanoma, even in light of advances with CTLA4 blockade and BRAF-targeted therapies for late-stage disease, says Vernon K. Sondak, M.D., chairman, department of cutaneous oncology, Moffitt Cancer Center, Tampa, Fla.

Differentiating benign nail pigmentations such as melanonychia from either nail or nail matrix melanoma is especially difficult in children because pediatric lesions present differently than they do in adults, according to Antonella Tosti, M.D., professor of the department of dermatology and cutaneous surgery, University of Miami Miller School of Medicine.

A recent clinical trial found that the dietary supplementation of oral zinc sulfate is ineffective in treating patients suffering from moderate-to-severe rosacea. The apparent failure of this particular clinical trial is of particular interest in that it was a near-duplicate of a 3-year-old clinical trial found in the literature, which showed that oral zinc supplementation was beneficial in the treatment of rosacea.

Latest Updated Articles